We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diphenyl Urea Compounds Inhibit Growth of Tuberculosis Bacteria

By LabMedica International staff writers
Posted on 13 Dec 2010
Using advanced genetic engineering techniques to produce enzymes from tuberculosis-causing Mycobacterium in Escherichia coli, researchers have identified a series of chemical compounds that inhibit the recombinant form of an essential enzyme.

Investigators at the University of Birmingham (United Kingdom) used plasmid technology to transfer the three Mycobacterium genes that code for the enzyme inosine monophosphate dehydrogenase (IMPDH) into cultures of E. More...
coli. They found that of the three enzyme isoforms only one, Mt-Guab2, was active in M. tuberculosis at an optimum pH of 8.5 and temperature of 37 °C. The investigators then used recombinant Mt-Guab2 to screen for potential inhibitory drugs.

The Investigators reported in the November 16, 2010, online edition of the journal Microbiology that from a group of 16 diphenyl urea (DPU) compounds, 3 were found to inhibit IMPDH. When tested against living Mycobacterium, these compounds prevented growth of both M. tuberculosis and M. smegmatis. When a plasmid overexpressing the Mt-Guab2 gene was implanted into M. smegmatis, 16 times the amount of DPU was required to inhibit growth.

"IMPDH is essential for cells to proliferate rapidly, which is one of the characteristics of microbial infection as well as human cancers. IMPDH has been used as a target in some anticancer drugs, as blocking the enzyme can prevent proliferation of the cell and induce cell death. Our findings show that inhibiting the bacterial version of IMPDH is a strategy that could be exploited for anti-TB drugs," said senior author Dr. Gurdyal Besra, professor of physiology and chemistry at the University of Birmingham. "The DPU compounds we tested have selective activity against Mycobacterium species, meaning that any future drugs based on these would be specific and would not affect human cells.”

"In the face of growing resistance to current therapies, we desperately need new treatments for TB that are safe and effective,” said Dr. Besra. "We are tapping the potential of a so far unexploited target which could lead to the synthesis of a novel antitubercular drug and our findings, so far are extremely encouraging.”

Related Links:
University of Birmingham



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.